ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts give ANI a consensus rating of Moderate Buy (five buys, three holds) with an average 1‑year price target of $107.33.
• Company insiders sold 27,860 shares worth about $2.11M over the last quarter (including SVPs Krista Davis and Thomas Rowland), and insiders now own 11.10% of the stock.
• Institutional investors hold 76.05% of ANI, with several funds materially increasing positions, while the stock trades near $76.48 (1‑year range $56.71–$99.50) and has a market cap of $1.71B.

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) have received an average rating of "Moderate Buy" from the eight brokerages that are presently covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $107.3333.

A number of research analysts have recently commented on the stock. Zacks Research cut shares of ANI Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, January 6th. Wall Street Zen cut shares of ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Saturday, March 14th. Weiss Ratings reissued a "hold (c+)" rating on shares of ANI Pharmaceuticals in a report on Monday, December 29th. Finally, Guggenheim increased their target price on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a "buy" rating in a report on Friday, January 16th.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, SVP Krista Davis sold 2,084 shares of the firm's stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $77.53, for a total transaction of $161,572.52. Following the completion of the transaction, the senior vice president owned 50,993 shares in the company, valued at approximately $3,953,487.29. This trade represents a 3.93% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Thomas Andrew Rowland sold 4,772 shares of the firm's stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $74.91, for a total transaction of $357,470.52. Following the transaction, the senior vice president owned 38,730 shares of the company's stock, valued at approximately $2,901,264.30. The trade was a 10.97% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 27,860 shares of company stock worth $2,111,581 over the last quarter. 11.10% of the stock is currently owned by corporate insiders.

Institutional Trading of ANI Pharmaceuticals

Several large investors have recently modified their holdings of ANIP. Pacer Advisors Inc. grew its position in ANI Pharmaceuticals by 1,821.1% in the 4th quarter. Pacer Advisors Inc. now owns 79,919 shares of the specialty pharmaceutical company's stock valued at $6,309,000 after purchasing an additional 75,759 shares during the period. Invesco Ltd. grew its position in ANI Pharmaceuticals by 26.0% in the 4th quarter. Invesco Ltd. now owns 189,836 shares of the specialty pharmaceutical company's stock valued at $14,986,000 after purchasing an additional 39,178 shares during the period. XTX Topco Ltd acquired a new stake in ANI Pharmaceuticals in the 4th quarter valued at $1,243,000. Susquehanna Portfolio Strategies LLC acquired a new stake in ANI Pharmaceuticals in the 4th quarter valued at $906,000. Finally, Tang Capital Management LLC grew its position in ANI Pharmaceuticals by 51.6% in the 4th quarter. Tang Capital Management LLC now owns 481,437 shares of the specialty pharmaceutical company's stock valued at $38,005,000 after purchasing an additional 163,937 shares during the period. Institutional investors and hedge funds own 76.05% of the company's stock.

ANI Pharmaceuticals Price Performance

NASDAQ:ANIP opened at $76.48 on Thursday. ANI Pharmaceuticals has a one year low of $56.71 and a one year high of $99.50. The company has a market cap of $1.71 billion, a P/E ratio of 22.76 and a beta of 0.44. The firm's fifty day moving average price is $76.22 and its two-hundred day moving average price is $82.11. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.71 and a quick ratio of 2.19.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI's product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.